Find your next paid study

Virginia Commonwealth UniversityNCT06636123

~$150 – $3,000

Actual pay is set by the research site.

Metastatic Castration-Resistant Prostate Cancer

A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

~$150 – $4,500

Actual pay is set by the research site.

AstraZenecaNCT06879041

Castration-resistant Prostate Cancer

Phase II Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

This is an open-label, multi-site study of AR Blockade with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy…

Edwin Posadas, MDNCT05534646

~$75 – $3,000

Actual pay is set by the research site.

Endometrial CancerGastric CancerMetastatic Castration-resistant Prostate Cancer+4 more

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination w…

~$75 – $3,000

Actual pay is set by the research site.

AstraZenecaNCT05489211

A Phase I Clinical Trial of an Infusion of Autologous Gamma Delta T Cells Genetically Engineered With a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients With Metastatic Castration Resistant Prostate Cancer

This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard…

H. Lee Moffitt Cancer Center and Research InstituteNCT06193486

~$150 – $3,000

Actual pay is set by the research site.

Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination With REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer

This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focuse…

Regeneron PharmaceuticalsNCT05125016

~$150 – $4,200

Actual pay is set by the research site.

Phase 3

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care …

~$50 – $2,250

Actual pay is set by the research site.

BioNTech SENCT07365995

Metastatic Castration Resistant Prostate CancermCRPCmCRPC (Metastatic Castration-resistant Prostate Cancer)+6 more

A Phase 1, First-in-Human, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FX-111 in Patients With Metastatic Castration-Resistant Prostate Cancer

The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resista…

~$150 – $4,200

Actual pay is set by the research site.

Flare Therapeutics Inc.

A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MT…

Syncromune, Inc.NCT06533644

~$75 – $2,800

Actual pay is set by the research site.

Prostate CancerMetastatic Castration-resistant Prostate CancerCastration-resistant Prostate Cancer

A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants With Prostate Cancer

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the …

Janux TherapeuticsNCT07545811

~$150 – $4,200

Actual pay is set by the research site.

Phase 4

A Pilot Study of 18F-DCFPyL-PSMA PET in Patients Receiving 177Lu-Vipivotide Tetraxetan Therapy for Metastatic Castrate-resistant Prostate Cancer

The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography …

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Carcinoma

Brigham and Women's HospitalNCT06099093

~$25 – $1,000

Actual pay is set by the research site.

Metastatic Castration-Resistant Prostate Cancer

A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targe…